Phase II, Double-Blind, Randomized, Single Center Trial Of Ovapuldencel-T (Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells In GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells In GM-CSF (MC) as a Component of Maintenance or Secondary Therapy in Patients With Stage III or IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma After Debulking Surgery and Adjuvant Chemotherapy

Trial Profile

Phase II, Double-Blind, Randomized, Single Center Trial Of Ovapuldencel-T (Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells In GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells In GM-CSF (MC) as a Component of Maintenance or Secondary Therapy in Patients With Stage III or IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma After Debulking Surgery and Adjuvant Chemotherapy

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Ovapuldencel-T (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Caladrius Biosciences; NeoStem Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 18 Sep 2015 Planned initiation date changed from 1 Oct 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top